Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TNG260 · 1 trial · 4 indications
To determine the MTD and RP2D(s) of TNG260 when administered in combination with pembrolizumab
To assess antineoplastic activity of TNG260 when administered in combination with pembrolizumab in participants with locally advanced unresectable or metastatic STK11-mutated solid tumors by measuring ORR, DOR, and PFS by RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Participants with STK11-mutant solid tumors will receive escalating doses of TNG260 in combination with pembrolizumab to estimate the MTD |
| Dose Expansion in NSCLC with KRAS Mutation | EXPERIMENTAL | Participants with STK11-mutant and KRAS-mutant NSCLC (squamous and non squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab |
| Dose Expansion in NSCLC with KRAS Wild type | EXPERIMENTAL | Participants with STK11-mutant and KRAS-wild type NSCLC (squamous and non-squamous) will receive TNG260 at the identified RP2D in combination with pembrolizumab |
| Dose Expansion in Advanced or Metastatic Solid Tumors | EXPERIMENTAL | Participants with STK11-mutant solid tumors (including but not limited to pancreatic, endometrial, cervical, breast, and carcinoma of unknown primary) will receive TNG260 at the identified RP2D in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| TNG260 | DRUG | CoREST inhibitor, administered orally |
| Pembrolizumab | DRUG | Pembrolizumab, an anti-PD-1 antibody, administered intravenously |
Inclusion Criteria: * Is ≥18 years of age at the time of signature of the main study ICF. * Has ECOG performance status of 0 or 1. * Has measurable disease based on RECIST v1.1. * All participants must have documented STK11 mutation in a solid tumor, which is identified through a validated analytic...
Top 20 of 90 competitors
TNG260 is an investigational small molecule developed by Tango Therapeutics, Inc. (ticker TNGX) for the treatment of non small cell lung cancer and other STK11 mutated solid tumors. It is being studied in combination with an anti-PD antibody and is currently in Phase 1 clinical development.
TNG260 is being developed for non small cell lung cancer and other solid tumors that carry STK11 mutations. It is evaluated in combination with an anti-PD antibody in a biomarker-selected patient population. TNG260 is investigational and has not been approved for any indication.
TNG260 targets the CoREST complex, a protein complex involved in chromatin regulation. By acting on this target, TNG260 is designed to address tumors with STK11 mutations, which are associated with resistance to immune checkpoint blockade. The CoREST complex is the molecular target of this small molecule.
TNG260 is being developed by Tango Therapeutics, Inc., a biotechnology company that trades under the ticker symbol TNGX. Tango Therapeutics is the sponsor of the clinical program evaluating TNG260 in STK11 mutated solid tumors, including non small cell lung cancer.
TNG260 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The Phase 1 program is currently active and evaluating TNG260 in combination with an anti-PD antibody in patients with STK11 mutated solid tumors.
TNG260 is being studied in the Phase 1 trial NCT05887492, titled Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors. The trial is active but not recruiting, has an enrollment of 126 participants, and is being conducted in the United States in adults aged 18 years and older.